In this episode, hosts Kyle Kruse and Richard Meiklejohn, interview Joseph ‘Yossi’ Mossel, CEO and Co-founder of Ibex Medical Analytics, about the company’s innovative use of AI in cancer diagnostics. Yossi discusses the critical problem of diagnostic errors in pathology, which can reach up to 10% in some labs, and the growing shortage of pathologists worldwide. Ibex’s AI technology acts as a “digital assistant” to pathologists, pre-analyzing cases and highlighting areas of concern, thereby increasing accuracy and efficiency.
Yossi emphasizes that Ibex’s AI is designed to augment, not replace, pathologists, allowing them to focus on complex cases while ensuring accuracy in routine diagnoses. The conversation touches on all the incredible data and partner foundations that been developed, which has led to significant deployments in Europe and the United States. Tune in to learn more about how Ibex is re-shaping pathology so you can be informed and inspired.
Key Takeaways:
- AI Augments, Doesn’t Replace: Ibex’s AI
serves as a “digital assistant” to pathologists, enhancing their
accuracy and efficiency rather than replacing their expertise. - Addressing Diagnostic Errors: The technology
significantly reduces diagnostic errors in cancer pathology, which can be
as high as 10% in some labs. - Overcoming Workforce Shortages: Ibex’s AI
helps alleviate the workload of pathologists, especially in the face of a
global shortage and an aging workforce. - Building Trust Through Data and Validation: Robust data sets and clinical validation are crucial for gaining
the trust of clinicians and ensuring the reliability of AI-driven
diagnostics. - Strategic Partnerships Drive Growth: Partnerships with major players like Roche Diagnostics and
AstraZeneca are key to Ibex’s market expansion and technology integration.
